2026 Volume 73 Issue 3.4 Pages 425-433
Objective:This prospective observational study investigated the effects of prior osteoporosis treatment on subsequent treatment with romosozumab (ROMO) followed by denosumab (DMAb) in female patients with primary osteoporosis. Methods:Treatment-naïve patients (Naïve group, n=15) and patients previously treated with teriparatide (TPTD group, n=15) or DMAb (DMAb group, n=41) were switched to ROMO for 12 months, followed by DMAb for 24 months. Bone mineral density (BMD) in the lumbar spine (LS) and total hip (TH) was evaluated every 6 months for 36 months. Results:At 12 months (after ROMO treatment) and 36 months (after ROMO+DMAb therapy), LS BMD respectively increased by 9.5% and 15.0% in the Naïve group, 9.7% and 18.6% in the TPTD group, and 4.3% and 8.3% in the DMAb group. The corresponding increases in TH BMD were 3.7% and 8.8%, 0.9% and 6.2%, and 0.9% and 4.6%. Conclusion:Previous therapy affected the BMD increase after treatment with ROMO but did not influence the increase after treatment with DMAb following ROMO. J. Med. Invest. 73 : 425-433, August, 2026